Nav: Home

Combination chemotherapy and immunotherapy effective in Phase II leukemia study

November 08, 2018

HOUSTON - A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

Results from the trial, led by Naval Daver, M.D., associate professor of Leukemia, were published in the Nov. 8 online issue of Cancer Discovery.

The study followed 70 patients with an average of two prior treatments for relapsed AML, and reported a 33 percent overall response with 22 percent of patients in complete remission. The drug combination was particularly effective in patients who had not previously received hypomethylating agents (HMAs) such as azacitidine or decitabine, with an overall response rate of 52 percent in these patients.

"In addition, bone marrow samples taken prior to treatment indicated a higher frequency of pre-therapy bone marrow CD3 and CD8 cells predicted for response to therapy," said Daver. "In particular, CD3 appeared to have a high sensitivity and specificity rate for predicting response, indicating it might serve as a reliable biomarker for selecting patients for this combination therapy."

Boosting immune checkpoint antibodies

Azacitidine is approved in the U.S. and Europe for patients with myelodysplastic syndrome (MDS), and is approved in Europe and commonly used in treating older patients with newly diagnosed AML. HHMAs such as azacitidine, promote anti-tumor signaling, and dampen anti-tumor immunity by increasing expression of immune checkpoint antibodies PD-1 and PD-L1 in AML and other cancers.

"Over the last decade, six PD-1, PD-L2 and CTLA-4 antibodies have been approved for over 25 indications in 10 tumor types in the U.S. and Europe," said Daver. "However, single agent PD-1 antibodies have shown little effect in patients with relapsed AML or high-risk MDS. This study was designed to assess whether the addition of nivolumab to azacitidine was safe and effective."

Treatment consisted of intravenously or subcutaneously administered azacytadine, and nivolumab given as an infusion. Eleven percent of patients experienced severe or potentially life threatening side effects, although the majority were successfully treated. Overall survival in all patients was 6.3 months. Survival in first relapsed patients was most encouraging at 10.6 months, which is double that of observed survival with azacitidine alone in similar patients at MD Anderson.

A randomized Phase III study with this combination in the frontline setting has been initiated. Other ongoing studies using this approach include a randomized Phase II study of azacytadine with or without PD-L1 inhibitor in frontline elderly AML patients, and a randomized trial of PD-1 inhibitors for eradication of minimal residual disease in high-risk AML patients in remission.

"We believe that implementation of clinical and immune biomarkers to select patients are likely to yield further improved outcomes with these types of therapies in AML," said Daver.
-end-
MD Anderson study team participants included Guillermo Garcia-Manero, M.D.; Prajwal Boddu; Mansour Alfayez, M.D.; Jorge Cortes, M.D.; Marina Konopleva, M.D., Ph.D.; Farhad Ravandi, M.D.; Elias Jabbour, M.D.; Tapan Kadia, M.D.; Naveen Pemmaraju, M.D.; Courtney DiNardo, M.D.; Michael Andreeff, M.D., Ph.D.; Sherry Pierce; Tauna Gordon; Steven Kornblau, M.D.; Wilmer Flores; and Hagop Kantarjian, M.D., all of the Department of Leukemia; Sreyashi Basu, Ph.D.; Zainab Alhamal; Jorge Blando; and James Allison, Ph.D., all of Immunology; Padmanee Sharma, of Genitourinary Medical Oncology; Graciela Nogueras Gonzalez; and Jing Ning, of Biostatistics; and Carlos Buesos-Ramos; Jeffrey Jorgensen; and Keyur Patel, of Hematopathology and Molecular Medicine.

The study was funded through a strategic collaboration with Bristol-Myers Squibb; the National Institutes of Health (CA100632 and CA016672); and the Myelodysplastic Syndromes & Acute Myeloid Leukemia Moon Shot™, part of MD Anderson's Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients' lives.

University of Texas M. D. Anderson Cancer Center

Related Leukemia Articles:

New leukemia treatment outperforms standard chemotherapies
Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies.
Team uncovers novel epigenetic changes in leukemia
UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.
Gene mutations cause leukemia, but which ones?
Watanabe-Smith's research, published today in the journal Oncotarget, sought to better understand one 'typo' in a standard leukemia assay, or test.
Halting lethal childhood leukemia
Scientists have discovered the genetic driver of a lethal childhood leukemia that affects newborns and infants and identified a targeted molecular therapy that halts the proliferation of leukemic cells.
Obesity-associated protein could be linked to leukemia development
Cancer researchers at the University of Cincinnati College of Medicine have found an obesity-associated protein's role in leukemia development and drug response which could lead to more effective therapies for the illness.
Tracking down therapy-resistant leukemia cells
Dr. Irmela Jeremias from Helmholtz Zentrum München and her colleagues have succeeded in finding a small population of inactive leukemia cells that is responsible for relapse of the disease.
Personalizing chemotherapy to treat pediatric leukemia
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
Putting a brake on leukemia cells
Cancer cells need a lot of energy in order to divide without limits.
Study provides new clues to leukemia resurgence after chemotherapy
For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.
Improving models of chronic lymphocytic leukemia
In this issue of JCI Insight, Nicholas Chiorazzi and colleagues at the Feinstein Institute for Medical Research sought to understand a model of chronic lymphocytic leukemia in which patient cancer cells are transplanted into immunocompromised mice.

Related Leukemia Reading:

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment
by Ashkan Emadi MD PhD (Editor), Judith E. Karp MD (Editor)

Leukemia: From Diagnosis to Winning the Battle
by Ryan Woelfel (Author), MD Robert Brian Berryman (Foreword), Connie Kouba (Foreword)

Childhood Leukemia: A Guide for Families, Friends & Caregivers
by Nancy Keene (Author)

NCCN Guidelines for Patients®: Chronic Lymphocytic Leukemia, 2018
by National Comprehensive Cancer Network® (NCCN®) (Author)

Johns Hopkins Patients' Guide to Leukemia
by Candis Morrison (Author), Charles L. Hesdorffer (Author)

The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Lifesaving Treatment
by Jessica Wapner (Author), Robert A. Weinberg PhD (Foreword)

100 Questions & Answers About Leukemia
by Jones & Bartlett Learning

Lymphomas and Leukemias: Cancer: Principles & Practice of Oncology, 10th edition
by Vincent T. DeVita Jr. MD (Author), Theodore S. Lawrence MD PhD (Author), Steven A. Rosenberg MD PhD (Author)

Six Years and Counting: Love, Leukemia, and the Long Road Onward
by Outskirts Press, Inc.

Leukemia (The Biology of Cancer)
by Donna M. Bozzone (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Where Joy Hides
When we focus so much on achievement and success, it's easy to lose sight of joy. This hour, TED speakers search for joy in unexpected places, and explain why it's crucial to a fulfilling life. Speakers include inventor Simone Giertz, designer Ingrid Fetell Lee, journalist David Baron, and musician Meklit Hadero.
Now Playing: Science for the People

#500 500th Episode
This week we turn 500! To celebrate, we're taking the opportunity to go off format, talk about the journey through 500 episodes, and answer questions from our lovely listeners. Join hosts Bethany Brookshire and Rachelle Saunders as we talk through the show's history, how we've grown and changed, and what we love about the Science for the People. Here's to 500 more episodes!